Quantinno Capital Management LP Increases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Quantinno Capital Management LP grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 46.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,541 shares of the medical equipment provider's stock after purchasing an additional 19,117 shares during the quarter. Quantinno Capital Management LP's holdings in Hologic were worth $4,364,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the period. Smithfield Trust Co raised its position in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares during the period. Finally, Sound Income Strategies LLC purchased a new stake in shares of Hologic during the 4th quarter valued at approximately $60,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Evercore ISI reduced their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley reduced their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Royal Bank of Canada dropped their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $77.42.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.88% of the company's stock.

Hologic Stock Down 0.4%

Shares of NASDAQ:HOLX traded down $0.20 during trading on Friday, hitting $54.28. The company's stock had a trading volume of 2,268,541 shares, compared to its average volume of 2,144,938. The business has a 50 day moving average price of $58.17 and a two-hundred day moving average price of $66.52. The company has a market capitalization of $12.10 billion, a PE ratio of 17.12, a P/E/G ratio of 2.14 and a beta of 0.54. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.03 earnings per share. As a group, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.